STOCK TITAN

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated news page for CRISPR Therapeutics (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRISPR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRISPR Therapeutics's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.94%
Tags
conferences
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
conferences
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

CRSP Stock Data

5.63B
79.19M
1.43%
66.81%
18.76%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Zug

About CRSP

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.